CODV (cross-over dual variable domains) -Ig, contain four polypeptide chains that form two dual variable domains (four antigen binding sites) with a cross-over orientation (Figure 1), which is attained by inverting the alignment of the cognate domains on one chain. In order to adopt the correct VH/VL pairing, linker combinations were designed and optimized using […]
The XmAb enables alterations with desirable effects to the Fc domain of the antibodies. The modification increases affinity to the neonatal Fc receptor which prevents the antibody from degradation. Hence, this interaction extends the antibody’s halflife of this therapeutic drug. In order to construct the XmAb format an antibody heavy and light chain and a […]
CrossMab technology enforces correct light chain association based on the domain crossover of immunoglobulin domains in the Fab region of the bispecific antibody. CrossMab technology allow the generation of various bispecific antibody formats, including bi- (1+1), tri- (2+1) and tetra-(2+2) valent bispecific antibodies, as well as non-Fc tandem antigen-binding fragment (Fab)-based antibodies. These formats may […]
cH IgG1 / κλ body involves the formation of in vitro display libraries with common heavy chains against two different antigens. κλ body share the same heavy chain but carry either κ or λ light chains. Three different chains (one heavy and two light) are then co-expressed in a single cell to generate a mixture containing two […]
Hetero H, forced HL IgG1/ DuetMab replaces the native disulfide bond in the CH1-CL interface with an engineered disulfide bond (fig. 1). This enhances cognate light chain pairing. Three different positions in the CH1-CL interface are possible candidates for favoring the formation of a novel disulfide bond. An amino acid on the HC and one […]
The Landscape of Neutralizing antibodies (NAb): Production, Mechanisms of Action (MOA), FDA approved-antibodies, and Functional assay FDA approved neutralizing antibodies (NAb) and our products 1. SARS-CoV-2 neutralizing antibodies (NAb) SARS-CoV-2, the novel coronavirus responsible for the ongoing COVID-19 pandemic, has been spreading rampantly. The global scientific community has responded rapidly to understand immune correlates of […]
Introduction In 2014 the World Health Organization (WHO) introduced new definitions for the assignment of antibody international nonproprietary names (INN). A modification of the existing definitions was required because advances in antibody engineering have made classification into the current three main antibody groups (i.e., chimeric, humanized and human) unclear. Unfortunately the new definitions suffer from […]
GeneMedi provides pre-made research class therapeutic antibodies & Fusion Protein with WHO-INN name. The INN named antibodies & Fusion Protein are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody or Fusion Protein for cell culture, in vitro/in vivo assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). Link to IMGT(Immunogenetics […]
Content index Antibody-drug Conjugate (ADC) Products Introduction Antibody-drug conjugate (ADC) is a new generation of therapeutic drugs, consisting of antibodies, small molecule drugs (payloads), and linkers connecting antibodies and payloads. The navigators target specific tumor cells and the small molecules enter tumor cells to kill them. ADCs may serve as a novel therapeutic modality for […]
Table of Contents GeneMedi VNTP™ Virus-like particles development service GM’s VNTP™ (VLP technology for Natural Transmembrane Protein) is a powerful capability for multi-transmembrane protein intact display. Please CONTACT to GM scientist for customized VLP development of your interest membrane protein target. What is virus like particles (VLP)? Virus-like particles (VLPs) are highly structured protein complexes that resemble […]
